Related Experiment Videos
Initial agonist treatment of Parkinson disease: a critique
1Department of Neurology, Geriatric Research, Education, and Clinical Center, Ann Arbor VAMC, University of Michigan, Ann Arbor, USA. ralbin@umich.edu
Neurology
|February 13, 2003
Abstract:
The evidence supporting initial dopamine agonist treatment of PD is reviewed. The two rationales for initial agonist treatment are reduced frequency of motor complications and possible relative neuroprotection by dopamine agonists. The basic science supporting these rationales is equivocal. The clinical evidence for advantages of initial agonist treatment is incomplete. More data are required to determine the optimal initial treatment for PD.